Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

As White House And FDA Ramp Up Coronavirus Research

Executive Summary

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

You may also be interested in...



Mylan Gives Up Exclusivity For US Kaletra Rival

Mylan has waived US exclusivity rights to its generic version of AbbVie’s Kaletra, which is being investigated as a treatment for COVID-19, after a week of activity that has seen Israel move to compulsory-license generic versions of the brand and the originator step back from enforcing related intellectual property worldwide.

India Bars Exports Of Hydroxychloroquine With Some Exceptions

India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.

Teva CEO Schultz To Sign On For Another Year

Teva CEO Kåre Schultz has received full backing to add another year onto his five-year contract, with a significant rise in compensation available if Teva’s shareholders say so later this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel